Purpose To investigate the effect of topical prostaglandin analogue use on the efficacy of selective laser trabeculoplasty (SLT) intraocular pressure (IOP) lowering in patients with open-angle glaucoma.
Introduction
Selective laser trabeculoplasty (SLT) is performed with a 532 nm Nd:YAG laser, and targets the pigmented cells of the trabecular meshwork. 1 SLT has been shown to produce similar intraocular pressure (IOP) lowering to argon laser trabeculoplasty (ALT). 2, 3 Histological studies suggest reduced damage to the trabecular meshwork with SLT, compared to ALT. 4 However, the use of SLT as a repeatable procedure in open-angle glaucoma requires further validation.
Various clinical studies have demonstrated the efficacy and safety of SLT in producing a sustained reduction in IOP. 1, 2, [5] [6] [7] [8] [9] [10] [11] SLT has also been shown to be effective as both primary treatment and as an adjunct to medical therapy. [9] [10] [11] A proportion of patients fail to respond to SLT and the reported success rates have varied considerably between published studies. The factors responsible for this variability are unclear. The effect of topical IOPlowering medications on the efficacy of SLT has not been investigated in depth. Given their efficacy and safety, prostaglandin analogues are now routinely used to control IOP. 12, 13 A recent report suggested that topical prostaglandin analogue use before and after SLT is associated with a greater reduction in IOP at 1 month after SLT. 14 In contrast, another study demonstrated reduced IOP lowering after SLT in eyes of patients taking prostaglandin analogues. 15 The aim of this study was to further investigate the effect of topical prostaglandin analogues on SLT efficacy. A secondary aim was to investigate other potential predictors of SLT success.
Materials and methods
We conducted a retrospective analysis of consecutive patients treated with SLT by a single clinician, from January 2006 to June 2007. All patients with open-angle glaucoma or ocular hypertension who underwent SLT for the first time and had a minimum of 6-month follow-up were included in the study. One eye was randomly selected for those patients who had SLT in both eyes. Data were collected by medical chart review and included demographic information, lens status, glaucoma risk factors, glaucoma type, glaucoma medication history, prior glaucoma surgery, and SLT parameters.
Surgical technique
All cases of SLT were performed by an experienced glaucoma surgeon (MC) with the q-switched frequencydoubled 532 nm Nd:YAG laser (Lumenis Selecta 700; Coherent Medical Group, Santa Clara, CA, USA). The inferior 1801 of the distal pigmented trabecular meshwork was treated with approximately 50 continuous but non-overlapping spots. An initial power setting of 0.8 W was titrated against micro-bubble formation. Patients were pretreated with topical 1% pilocarpine 1 h before SLT and were not given topical steroids after treatment.
Outcome parameters
The primary outcome of this study was IOP lowering 6 months after SLT. To provide a baseline IOP for each eye, Goldmann applanation IOP measurements from three separate pre-laser visits occurring over 3 months were recorded and averaged. Post-laser IOP was recorded at the follow-up visit occurring closest to 3 and 6 months. A 'successful' SLT outcome was defined as a reduction in IOP of 20% or more compared to baseline, without the need for additional glaucoma intervention (further SLT, trabeculectomy surgery, or addition of a glaucoma medication). Cases were regarded as unsuccessful if they underwent further glaucoma intervention at any time during follow-up. We chose this definition of success because it is the most commonly used in the SLT literature. 5, 2, 7, 10, 11, 16 To analyse the effect of prostaglandin analogues on SLT efficacy, we categorized eyes according to whether they received a topical prostaglandin analogue (bimatoprost, latanoprost, or travoprost) as part of their glaucoma medical therapy before laser and during the follow-up period. The eyes that did not receive prostaglandins included those not receiving any topical medications and eyes treated with other topical agents (b-blockers, a-2 agonists, or carbonic anhydrase inhibitors). Patients who were prescribed glaucoma medications for less than 3 months before SLT or those who had glaucoma medications discontinued or altered during the course of follow-up were excluded from this study. Medications were altered in these patients due to either side effects, a lack of clinical response, or patient preference. In a separate analysis, we also compared successful and non-successful SLT treatments, independent of topical medication use, to investigate possible patient and ocular factors that may predict SLT success.
Statistical analysis
Statistical analysis was performed with the GraphPad Prism Software for Windows and SPSS 16.0 statistical software package (SPSS Inc., Chicago, IL, USA). Statistical significance in the differences between groups (defined as Po0.05) was detected with the Student's t-test or one-way analysis of variance for continuous variables and with the w 2 -test or Fisher's exact test for categorical variables. Success rates between groups were compared with Kaplan-Meier survival analysis and logrank (Mantel-Cox) tests. Association between SLT outcome and various patient characteristics, including age, sex, type of glaucoma, previous glaucoma surgery, and other glaucoma risk factors was assessed by logistic regression. Odds ratios (OR) with 95% confidence intervals (CI) were given to estimate the relative risk.
We certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers were followed during this research.
Results
A total of 123 eyes were identified during the study period of which 74 eyes received prostaglandin analogues before and after SLT and 49 eyes received either other non-prostaglandin agents or no medications. The distribution of topical medication use in each treatment group is presented in Table 1 . The treatment groups were similar in terms of demographics and baseline characteristics ( Table 1) .
The mean baseline IOP (±SD) was 20.9±4.5 in the prostaglandin group and 19.8 ± 4.3 mm Hg in the nonprostaglandin group (Figure 1 ). There was no statistical difference in mean IOP between each treatment group at baseline (P ¼ 0.20), at 3 months, (P ¼ 0.54), or 6 months after SLT (P ¼ 0.72, unpaired t-test). At the last follow-up period, the reduction in IOP from baseline was also Effect of topical prostaglandin analogues on SLT D Singh et al Eyes received prostaglandin analogues Eyes did not receive prostaglandin analogues Effect of topical prostaglandin analogues on SLT D Singh et al similar between treatment groups, with IOP decreasing by a mean of 3.9 ± 4.8 mm Hg in the prostaglandin group and 4.6 ± 3.6 mm Hg in the non-prostaglandin group (P ¼ 0.43, unpaired t-test). We estimated the power of this study to detect a clinically relevant difference of 2 mm Hg in mean IOP between the two treatment groups was 80% (a ¼ 0.05, two tailed). A total of 29 eyes (39%) in the prostaglandin group and 22 eyes (45%) in the non-prostaglandin group met SLT success criteria (X20% reduction in IOP at last follow-up without further glaucoma interventions). Kaplan-Meier survival analysis, using this definition of SLT success, showed no significant difference between treatment groups (Figure 2 , log-rank P ¼ 0.68).
In a subgroup analysis, IOP lowering at 6 months was similar in eyes that received no glaucoma medications, monotherapy with or without a prostaglandin analogue, or combination therapy with or without prostaglandin analogues (Table 2 , P ¼ 0.81, one-way analysis of variance).
To investigate whether certain demographic characteristics, glaucoma risk factors, previous ALT or glaucoma surgery, or lens status predicted SLT success in this patient sample, we compared the distribution of these variables between the success and non-success groups (Table 3) . Analysis by multivariable logistic regression found a higher baseline IOP to be a predictor of SLT success (Table 3) , however other factors did not correlate with SLT outcome. Abbreviations: ALT, argon laser trabeculoplasty; BCVA, best-corrected visual acuity; CI, confidence interval; IOP, intraocular pressure; logMAR, logarithmic minimum angle of resolution; OHTN, ocular hypertension; OR, odds ratio; POAG, primary open-angle glaucoma; SD, standard deviation; SLT, selective laser trabeculoplasty. Success was defined as X20% IOP reduction from baseline to last follow-up after SLT without further glaucoma interventions.
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Conclusion
The value of IOP lowering in slowing glaucoma progression as determined by either visual field loss or change in optic nerve head and retinal nerve fibre layer morphology has been established by various large prospective randomized studies. [17] [18] [19] [20] SLT is a relatively new treatment available to lower IOP in glaucoma but the factors that influence its efficacy remain to be elucidated. As a primary therapy for open-angle glaucoma or ocular hypertension, SLT and medical therapy with prostaglandin analogues have shown similar efficacy. 9, 11 Prostaglandin analogues are now the first choice for topical medical therapy in many glaucoma patients. We investigated possible synergism between SLT and prostaglandin analogues in reducing IOP in patients with open-angle glaucoma.
This study found that the reduction in IOP following SLT and success rate was similar in eyes receiving topical prostaglandin analogues before and after SLT (in combination with other non-prostaglandin agents) compared to eyes that received either no glaucoma medications or other non-prostaglandin agents. Furthermore, SLT efficacy was found to be similar in eyes receiving no topical medications, single medications, or multiple medications. There was a minor difference between the treatment groups in terms of previous ALT or trabeculectomy (Table 3) . However when the small group of patients in the prostaglandin group who had received previous glaucoma surgery or ALT was excluded, no significant difference in IOP lowering was observed.
Given the retrospective nature of this study, it was not possible to use a predetermined protocol for administering medications during the follow-up period. In an effort to remove this confounding variable, we excluded eyes that had medications altered during follow-up. Although this may introduce a selection bias into the study, the excluded cases were quite similar to the rest of the study population in terms of baseline IOP and other demographic characteristics.
Our findings differ to a recent study by Scherer, 14 who found eyes treated with prostaglandin analogues before and after 1801 SLT had a greater reduction in IOP and a higher success rate at 30 days after treatment (defined by the same criteria as our study) than eyes receiving nonprostaglandin medications. Interestingly, this earlier study reported an unusually small reduction in IOP in eyes treated with non-prostaglandin medications, 14 whereas results in prostaglandin-treated eyes are quite similar to our findings. Elsewhere, in a retrospective review, prostaglandin use was associated with a higher, but statistically non-significant rate of SLT failure (defined as those patients not achieving a 20% reduction in IOP after 1801 laser treatment). 15 SLT outcomes vary considerably in published literature, where reports of IOP reduction range from 12 to 30% of baseline and success rates range from 20 to 96%, depending on the definition of success.
5,1,2,6-11, 15 The mean reduction in IOP and success rate observed in our study is lower than a number of other studies. 1, 2, [9] [10] [11] This difference may be explained by the lower baseline IOP in our patient cohort. Indeed, we found a higher baseline IOP to be a significant predictor of success following SLT, which is consistent with a number of other reports. 5, 7, 15 Our study also differs from the majority of prior studies in the use of three separate baseline IOP measurements to reduce influence from regression to the mean.
Analysis of patient characteristics and glaucoma risk factors showed that age, sex, family history of glaucoma, diabetes mellitus, hypertension, pseudophakia, myopia, type of glaucoma, and previous treatment for glaucoma did not predict a successful SLT outcome. This is in agreement with a number of other studies. 5, 15 In conclusion, this study presents data showing that the long-term efficacy of SLT in terms of IOP reduction is not influenced by treatment with topical prostaglandin analogues.
